49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-012059-47-DE
(EUCTR)
12/08/201021/01/2010A phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNa-Kinoid in adult subjects with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus ErythematosusA phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNa-Kinoid in adult subjects with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE)
MedDRA version: 12.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus
Product Name: IFN-a2b Kinoid
Product Code: IFN-K
INN or Proposed INN: Not assigned yet
Other descriptive name: IFN-a 2b Kinoid Drug Substance
Neovacs SANULLNot RecruitingFemale: yes
Male: yes
28Phase 1;Phase 2France;Belgium;Bulgaria;Germany
2EUCTR2009-012059-47-FR
(EUCTR)
07/05/201002/02/2010A phase I-II, randomized, observer-blind, placebo-controlled, dose escalation study to evaluate the safety and immune responses of various doses of Neovacs’ IFNa-Kinoid in adult patients with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus ErythematosusA phase I-II, randomized, observer-blind, placebo-controlled, dose escalation study to evaluate the safety and immune responses of various doses of Neovacs’ IFNa-Kinoid in adult patients with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE)
MedDRA version: 12.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus
Product Name: IFN-a2b Kinoid
Product Code: IFN-K
INN or Proposed INN: Not assigned yet
Other descriptive name: IFN-a 2b Kinoid Drug Substance
Neovacs SANULLNot Recruiting Female: yes
Male: yes
28 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Belgium;Bulgaria;Germany
3EUCTR2009-012059-47-BG
(EUCTR)
23/04/201015/04/2010A phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNa-Kinoid in adult subjects with Systemic Lupus Erythematosus.A phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNa-Kinoid in adult subjects with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE)
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Product Name: IFN-a2b Kinoid
Product Code: IFN-K
INN or Proposed INN: Not assigned yet
Other descriptive name: IFN-a 2b Kinoid Drug Substance
Neovacs SANULLNot RecruitingFemale: yes
Male: yes
28Phase 1;Phase 2France;Belgium;Bulgaria;Germany
4EUCTR2009-012059-47-BE
(EUCTR)
28/01/201005/01/2010A phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNa-Kinoid in adult subjects with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus ErythematosusA phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNa-Kinoid in adult subjects with Systemic Lupus Erythematosus. - IFN-Kinoid in Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE)
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Product Name: IFN-a2b Kinoid
Product Code: IFN-K
INN or Proposed INN: Not assigned yet
Other descriptive name: IFN-a 2b Kinoid Drug Substance
Neovacs SANULLNot RecruitingFemale: yes
Male: yes
28Phase 1;Phase 2France;Belgium;Bulgaria;Germany